Literature DB >> 16011514

Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.

Sadamu Homma1, Hideo Komita, Yukiko Sagawa, Tsuneya Ohno, Gotaro Toda.   

Abstract

When BALA/c mice with BNL hepatocellular carcinoma (HCC) were treated with dendritic cells fused with BNL cells (DC/BNL) and recombinant murine interleukin (IL)-12, tumour development was significantly suppressed, whereas treatment with either DC/BNL or IL-12 alone did not show a tumour-suppressive effect. Antitumour activity induced by DC/BNL + IL-12 was abrogated by depletion of CD4+ T cells, but not by depletion of CD8+ T cells or natural killer cells. Splenic CD4+ T cells and CD8+ T cells from DC/BNL-treated mice showed cytotoxic activity against BNL cells after 3 days of incubation with DC/BNL, although BNL cells do not express major histocompatibility complex (MHC) class II molecules even after treatment with interferon (INF)-gamma. Furthermore, CD4+ T cells killed syngeneic-irrelevant CT26 cells and even allogeneic Hepa1-6 cells. This cytotoxicity was blocked by concanamycin A, but not by an anti-Fas ligand (FasL) monoclonal antibody, indicating that cytotoxic activity was mediated by perforin. Immunofluorescence microscopy demonstrated that abundant CD4+ T cells and MHC class II-positive macrophages, but not CD8(+) T cells, had infiltrated tumour tissue in mice treated with DC/BNL + IL-12. Flow cytometric analysis of tumour-infiltrating cells in mice treated with DC/BNL + IL-12 showed increases in CD4+ T cells and MHC class II+ CD11b+ cells but not in CD8+ T cells or MHC class I+ CD11b+ cells. Our results suggest that, in BNL-bearing mice treated with DC/BNL + IL-12, tumour macrophages activated by INF-gamma produced by IL-12-stimulated T cells might present BNL tumour antigens and activate DC/BNL-primed CD4+ cytotoxic T lymphocytes (CTLs) in a MHC class II-dependent manner, leading to perforin-mediated bystander killing of neighbouring MHC class II-negative tumour cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16011514      PMCID: PMC1782174          DOI: 10.1111/j.1365-2567.2005.02179.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  42 in total

1.  IL-12 receptor (IL-12R) expression and accumulation of IL-12R beta 1 and IL-12R beta 2 mRNAs in CD4+ T cells by costimulation with B7-2 molecules.

Authors:  O Igarashi; H Yamane; S Imajoh-Ohmi; H Nariuchi
Journal:  J Immunol       Date:  1998-02-15       Impact factor: 5.422

Review 2.  Dendritic cells presenting tumor antigen.

Authors:  M R Shurin
Journal:  Cancer Immunol Immunother       Date:  1996-11       Impact factor: 6.968

3.  Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells.

Authors:  J Gong; D Chen; M Kashiwaba; D Kufe
Journal:  Nat Med       Date:  1997-05       Impact factor: 53.440

Review 4.  Cytotoxic lymphocytes: redirecting the cell-mediated immune response for the therapy of cancer.

Authors:  M H Kershaw; J A Trapani; M J Smyth
Journal:  Ther Immunol       Date:  1995-06

Review 5.  Perforin and lymphocyte-mediated cytolysis.

Authors:  C C Liu; P M Persechini; J D Young
Journal:  Immunol Rev       Date:  1995-08       Impact factor: 12.988

Review 6.  Tumor-induced immune dysfunction: the macrophage connection.

Authors:  K D Elgert; D G Alleva; D W Mullins
Journal:  J Leukoc Biol       Date:  1998-09       Impact factor: 4.962

7.  Contrasting effects of TGF-beta 1 and TNF-alpha on the development of dendritic cells from progenitors in mouse bone marrow.

Authors:  Y Yamaguchi; H Tsumura; M Miwa; K Inaba
Journal:  Stem Cells       Date:  1997       Impact factor: 6.277

8.  CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.

Authors:  D Mumberg; P A Monach; S Wanderling; M Philip; A Y Toledano; R D Schreiber; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

9.  Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine.

Authors:  Toshio Iinuma; Sadamu Homma; Tetsuo Noda; Donald Kufe; Tsuneya Ohno; Gotaro Toda
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

10.  Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.

Authors:  K Inaba; M Inaba; N Romani; H Aya; M Deguchi; S Ikehara; S Muramatsu; R M Steinman
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

View more
  14 in total

1.  Exosomes from heat-stressed tumour cells inhibit tumour growth by converting regulatory T cells to Th17 cells via IL-6.

Authors:  Danfeng Guo; Yinghu Chen; Shoujie Wang; Lei Yu; Yingying Shen; Haijun Zhong; Yunshan Yang
Journal:  Immunology       Date:  2018-01-02       Impact factor: 7.397

2.  Expansion of interferon-gamma-producing multifunctional CD4+ T-cells and dysfunctional CD8+ T-cells by glypican-3 peptide library in hepatocellular carcinoma patients.

Authors:  Yanhui Xu; Hong Li; Rui Lin Gao; Oluwasayo Adeyemo; Maxim Itkin; David E Kaplan
Journal:  Clin Immunol       Date:  2011-02-26       Impact factor: 3.969

Review 3.  Immunotherapy for hepatocellular carcinoma: From basic research to clinical use.

Authors:  Yu-Peng Hong; Zi-Duo Li; Pankaj Prasoon; Qi Zhang
Journal:  World J Hepatol       Date:  2015-05-08

4.  Dendritic cell based genetic immunization stimulates potent tumor protection dependent on CD8 CTL cells in the absence of autoimmunity.

Authors:  Sheng Zhang; Weiyi Huang
Journal:  J Cancer Res Clin Oncol       Date:  2008-02-26       Impact factor: 4.553

5.  Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses.

Authors:  S Homma; Y Sagawa; M Ito; T Ohno; G Toda
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

6.  CD4+ T-cell-dependent tumour rejection in an immune-privileged environment requires macrophages.

Authors:  Dru S Dace; Peter W Chen; Jerry Y Niederkorn
Journal:  Immunology       Date:  2007-10-17       Impact factor: 7.397

7.  Telomerase activity in tumor and remnant liver as predictor of recurrence and survival in hepatocellular carcinoma after resection.

Authors:  Yan-Shen Shan; Yu-Hsiang Hsieh; Pin-Wen Lin
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

8.  Tumor-specific CD4+ T cells develop cytotoxic activity and eliminate virus-induced tumor cells in the absence of regulatory T cells.

Authors:  Ilseyar Akhmetzyanova; Gennadiy Zelinskyy; Simone Schimmer; Sven Brandau; Petra Altenhoff; Tim Sparwasser; Ulf Dittmer
Journal:  Cancer Immunol Immunother       Date:  2012-08-14       Impact factor: 6.968

9.  Conditions for the generation of cytotoxic CD4(+) Th cells that enhance CD8(+) CTL-mediated tumor regression.

Authors:  Kunyu Li; Margaret Baird; Jianping Yang; Chris Jackson; Franca Ronchese; Sarah Young
Journal:  Clin Transl Immunology       Date:  2016-08-12

Review 10.  Fighting Viral Infections and Virus-Driven Tumors with Cytotoxic CD4+ T Cells.

Authors:  Elena Muraro; Anna Merlo; Debora Martorelli; Michela Cangemi; Silvia Dalla Santa; Riccardo Dolcetti; Antonio Rosato
Journal:  Front Immunol       Date:  2017-02-27       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.